• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    HC Wainwright & Co. reiterated coverage on Phio Pharmaceuticals with a new price target

    6/14/21 6:22:20 AM ET
    $PHIO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $PHIO alert in real time by email
    HC Wainwright & Co. reiterated coverage of Phio Pharmaceuticals with a rating of Buy and set a new price target of $6.00 from $4.00 previously
    Get the next $PHIO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $PHIO

    DatePrice TargetRatingAnalyst
    6/5/2025$14.00Buy
    H.C. Wainwright
    More analyst ratings

    $PHIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Carson Lisa Cabott

      3 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      6/18/25 4:30:56 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chairman, Pres & CEO Bitterman Robert J bought $4,840 worth of shares (2,000 units at $2.42), increasing direct ownership by 8% to 27,149 units (SEC Form 4)

      4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      6/11/25 5:00:01 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ferrara Robert L bought $6,050 worth of shares (2,500 units at $2.42), increasing direct ownership by 19% to 15,666 units (SEC Form 4)

      4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      6/11/25 4:59:45 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHIO
    SEC Filings

    See more
    • Phio Pharmaceuticals Corp. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)

      6/25/25 8:46:08 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Corp. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

      8-K - Phio Pharmaceuticals Corp. (0001533040) (Filer)

      6/12/25 7:49:03 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Phio Pharmaceuticals Corp.

      10-Q - Phio Pharmaceuticals Corp. (0001533040) (Filer)

      5/15/25 4:34:57 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright resumed coverage on Phio Pharmaceuticals with a new price target

      H.C. Wainwright resumed coverage of Phio Pharmaceuticals with a rating of Buy and set a new price target of $14.00

      6/5/25 7:35:43 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Phio Pharmaceuticals with a new price target

      HC Wainwright & Co. reiterated coverage of Phio Pharmaceuticals with a rating of Buy and set a new price target of $6.00 from $4.00 previously

      6/14/21 6:22:20 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHIO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chairman, Pres & CEO Bitterman Robert J bought $4,840 worth of shares (2,000 units at $2.42), increasing direct ownership by 8% to 27,149 units (SEC Form 4)

      4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      6/11/25 5:00:01 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Ferrara Robert L bought $6,050 worth of shares (2,500 units at $2.42), increasing direct ownership by 19% to 15,666 units (SEC Form 4)

      4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      6/11/25 4:59:45 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chairman, Pres & CEO Bitterman Robert J bought $4,125 worth of shares (1,500 units at $2.75), increasing direct ownership by 6% to 25,149 units (SEC Form 4)

      4 - Phio Pharmaceuticals Corp. (0001533040) (Issuer)

      6/10/25 4:43:57 PM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort

      -Phio's lead clinical siRNA compound PH-762 demonstrates supportive safety profile in fourth cohort, permitting dose escalation in expected final cohortMarlborough, Massachusetts--(Newsfile Corp. - June 25, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that the Safety Monitoring Committee (SMC) recommended dose escalation in its Phase 1b clinical trial designed to evaluate the safety and tolerability of intratumoral (IT) PH-762 in the treatment of Stages 1, 2, and 4 cutaneous squamous cell carcinoma (cSCC), Stage 4 m

      6/25/25 7:45:00 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

      Registration Link for Presentation and live Q&A to take place, Monday, June 30, 2025 at 10:00 am ESTMarlborough, Massachusetts--(Newsfile Corp. - June 24, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Recently, positive interim safety and efficacy results were rep

      6/24/25 7:45:00 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Announces Participation in the Sidoti Micro-Cap Virtual Investor Conference

      Registration Link for Presentation to take place Thursday, May 22, 2025 at 10:00 AM ETMarlborough, Massachusetts--(Newsfile Corp. - May 19, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Mr. Bitterman will also host one-on-one meetings with investors at the conferen

      5/19/25 7:45:00 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

      Registration Link for Presentation and live Q&A to take place, Monday, June 30, 2025 at 10:00 am ESTMarlborough, Massachusetts--(Newsfile Corp. - June 24, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Recently, positive interim safety and efficacy results were rep

      6/24/25 7:45:00 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series

      Registration Link for Presentation and live Q&A to take place, Wednesday, May 7, 2025 at 2:00 pm ESTMarlborough, Massachusetts--(Newsfile Corp. - May 1, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company developing therapeutics using its proprietary INTASYL® gene silencing technology to eliminate cancer. Phio announced today that Mr. Robert Bitterman, CEO and Chairman of the Board, Phio Pharmaceuticals will present an update on the company's proprietary INTASYL siRNA technology and progress on the on-going clinical trial with lead compound PH-762 for treatment of skin cancers. Phio's presentation and live Q&A will take place on Wednesday, May

      5/1/25 7:45:00 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Phio Pharmaceuticals Announces Appointment of David H. Deming to Board of Directors

      Marlborough, Massachusetts--(Newsfile Corp. - February 20, 2025) - Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage biotechnology company developing therapeutics that use its INTASYL® siRNA gene silencing technology designed to make the body's immune cells more effective in killing cancer cells. Phio announced today the appointment of Mr. David H. Deming to the Phio Board of Directors, effective Feb 19, 2025. Mr. Deming will immediately serve as a member of the Board's Nominating Committee. Following the appointment of Mr. Deming, the Board now comprises 6 directors, 5 of whom are independent."Mr. Deming's extensive experience in in the biopharma sector, both through his investme

      2/20/25 7:45:00 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $PHIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp.

      SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)

      11/13/24 11:20:45 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp. (Amendment)

      SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)

      2/6/24 10:30:10 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Phio Pharmaceuticals Corp. (Amendment)

      SC 13G/A - Phio Pharmaceuticals Corp. (0001533040) (Subject)

      2/8/23 6:07:04 AM ET
      $PHIO
      Biotechnology: Pharmaceutical Preparations
      Health Care